"10.1371_journal.pone.0050342","plos one","2012-11-30T00:00:00Z","Francesca Margheri; Nicola Schiavone; Laura Papucci; Lucia Magnelli; Simona Serratì; Anastasia Chillà; Anna Laurenzana; Francesca Bianchini; Lido Calorini; Eugenio Torre; Javier Dotor; Esperanza Feijoo; Gabriella Fibbi; Mario Del Rosso","Department of Experimental Pathology and Oncology, University of Florence, Florence, Italy; Istituto Toscano Tumori, Florence, Italy; Department of Oncohematology, Istituto Tumori Giovanni Paolo II, Bari, Italy; DIGNA Biotech, Pamplona, Spain","Conceived and designed the experiments: FM NS LP LM SS AC AL FB LC JD EF GF MDR. Performed the experiments: FM NS LP LM SS AC AL FB LC ET. Analyzed the data: FM NS LP LM LC JD EF GF MDR. Contributed reagents/materials/analysis tools: NS LP LM LC JD EF GF MDR. Wrote the paper: FM NS LP LM JD EF GF MDR.","Dr. Javier Dotor and Dr. Esperanza Feijoo, who first designed anti-TGF-beta peptides used in this study, have an affiliation with the commercial funder of this research (DIGNA), as founders of this Spin-off company of the University of Navarra (Spain). Both Peptides P144 and P17 used in this study (whose characteristics are detailed in references 37 and 38) have been patented by DIGNA Biotech Company and are actually in clinical phase III for topic use in patients affected by the localized form of Scleroderma to treat local fibrosis and to prevent its worsening. However, this does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials..","2012","11","Francesca Margheri","FM",14,TRUE,13,10,9,8,TRUE,TRUE,FALSE,0,NA,FALSE
